Originally published as JCO Early Release 10.1200/JCO.2008.21.1755 on March 2 2009

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petrelli, N. J. Search for Related Content PubMed PubMed Citation Articles by Petrelli, N. J. Related Articles Related Articles Social Bookmarking                            What's this?

Bevacizumab and Postoperative Complications After Hepatic Surgery for Colorectal Metastases

Helen F. Graham Cancer Center at Christiana Care, Newark, DE

To the Editor:

I congratulate Kesmodel et al¹ from The University of Texas M. D. Anderson Cancer Center concerning their recent article in Journal of Clinical Oncology proposing that preoperative bevacizumab does not significantly increase postoperative complications in patients undergoing liver surgery for colorectal cancer metastases. The congratulations are not due to the superiority of their data, but importantly to their self-criticism of the data. The authors concluded that neither the use of bevacizumab nor the timing of bevacizumab administration increases surgical complication rates. However, they qualify their statement by relating that confirmatory prospective studies are required. This is important because in the discussion section of their article, they indeed relate that because their study is retrospective from a single institution with a small number of patients (81 patients in the chemotherapy-plus-bevacizumab group and 44 patients in the chemotherapy-alone group), definitive conclusions about the safety of neoadjuvant bevacizumab and its timing of discontinuation cannot be made. Since the type of chemotherapy, the decision to use bevacizumab, and the duration of chemotherapy and bevacizumab administration, along with the timing of surgical consultation, are at the discretion of the treating physician, the conclusion of their manuscript is preliminary and, as they have stated, must be confirmed prospectively.

This group of investigators has a significant experience with hepatic resection of colorectal metastases and continues to recommend waiting at least 6 weeks from discontinuation of bevacizumab before hepatic resection is performed. We certainly can learn from retrospective series, but to the credit of these authors, the self-criticism of their data is laudable. Unfortunately, this is not the case with many retrospective series that appear in the literature, whereupon readers will take the conclusions as definitive.

Many of the issues discussed by the authors of this article will be part of the aims of an NCI phase III clinical trial to evaluate neoadjuvant versus adjuvant infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab in patients with potentially resectable hepatic colorectal metastases. The concept of this trial was developed by the Gastrointestinal Leadership of the National Surgical Adjuvant Breast and Bowel Project, American College of Surgeons Oncology Group, and the North Central Cancer Treatment Group. This trial has received approval by the National Cancer Institute Colon Task Force and will soon be presented to the National Cancer Institute Gastrointestinal Steering Committee for discussion. The trial will randomly assign patients with resectable colorectal hepatic metastases to FOLFOX plus bevacizumab before resection followed by the same combination postoperatively versus hepatic resection first followed by postoperative FOLFOX plus bevacizumab. Although the primary end point will be progression-free survival, many secondary end points will be evaluated, including perioperative morbidity related to the agents utilized.

I congratulate the authors for discussing the shortcomings of their retrospective review, which should be an example for other authors.

AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

REFERENCE

1. Kesmodel SB, Ellis LM, Lin E, et al: Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26:5254–5260, 2008.[Abstract/Free Full Text]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Articles

• In Reply
  Barry W. Feig, Susan B. Kesmodel, Lee M. Ellis, George J. Chang, and Miguel A. Rodriguez-Bigas
  JCO 2009 27: 1918 [Full Text]
• Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases
  Susan B. Kesmodel, Lee M. Ellis, E. Lin, George J. Chang, Eddie K. Abdalla, Scott Kopetz, Jean-Nicolas Vauthey, Miguel A. Rodriguez-Bigas, Steven A. Curley, and Barry W. Feig
  JCO 2008 26: 5254-5260 [Abstract] [Full Text]

This article has been cited by other articles:

				B. W. Feig, S. B. Kesmodel, L. M. Ellis, G. J. Chang, and M. A. Rodriguez-Bigas In Reply J. Clin. Oncol., April 10, 2009; 27(11): 1918 - 1918. [Full Text] [PDF]

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petrelli, N. J. Search for Related Content PubMed PubMed Citation Articles by Petrelli, N. J. Related Articles Related Articles Social Bookmarking                            What's this?